The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II

American Heart Journal

Volumn 149, Issue 6, 2005, Pages 977-983

  Armani, Annemarie ^a   Becker, Richard C ^b  

^a IntraMed   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIET; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; THROMBOSIS; WEIGHT REDUCTION;

EID: 20544471438     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.12.032     Document Type: Review

References (104)

1. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
2. B. Schieffer, E. Schieffer, and D. Hilifiker-Kleiner Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability Circulation 101 2000 1372 1378
3. L. Gu, Y. Okada, and S.K. Clinton Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice Mol Cell 2 1998 275 281
4. E. Falk, P.K. Shah, and V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
5. M.J. Davies Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 Circulation 94 1996 2013 2020
6. A.P. Burke, A. Farb, and G.T. Malcom Coronary risk factors and plaque morphology in men with coronary disease who died suddenly N Engl J Med 336 1997 1276 1282
7. P. Libby, D. Egan, and S. Skarlatos Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research Circulation 96 1997 4095 4103
8. P.R. Moreno, E. Falk, and I.F. Palacios Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture Circulation 90 1994 775 778
9. A.C. van der Wal, A.E. Becker, and C.M. van der Loos Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 1994 36 44
10. A. Maseri Inflammation, atherosclerosis, and ischemic events-exploring the hidden side of the moon N Engl J Med 336 1997 1014 1016
11. P.M. Ridker, N. Rifai, and M.J. Stampfer Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
12. T.B. Harris, L. Ferrucci, and R.P. Tracy Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly Am J Med 106 1999 506 512
13. G. Liuzzo, A. Buffon, and L.M. Biasucci Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina Circulation 98 1998 2370 2376
14. L.M. Biasucci, G. Liuzzo, and G. Fantuzzi Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Circulation 99 1999 2079 2084
15. P.M. Ridker, N. Rifai, and M. Pfeffer Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction Circulation 101 2000 2149 2153
16. S.J. Hwang, C.M. Ballantyne, and A.R. Sharrett Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study Circulation 96 1997 4219 4225
17. P.M. Ridker, C.H. Hennekens, and B. Roitman-Johnson Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy mean Lancet 351 1998 88 92
18. P. Saikku, M. Leinonen, and K. Mattila Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction Lancet 2 1988 983 986
19. J.L. Melnick, E. Adam, and M.E. DeBakey Possible role of cytomegalovirus in atherogenesis JAMA 263 1990 2204 2207
20. M.A. Mendall, P.M. Goggin, and N. Molineaux Relation of Helicobacter pylori infection and coronary heart disease Br Heart J 71 1994 437 439
21. J.T. Grayston, C.C. Kuo, and A.S. Coulson Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery Circulation 92 1995 3397 3400
22. J.B. Muhlestein, E.H. Hammond, and J.F. Carlquist Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease J Am Coll Cardiol 27 1996 1555 1561
23. F.J. Nieto, E. Adam, and P. Sorlie Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis Circulation 94 1996 922 927
24. N.J. Wald, M.R. Law, and J.K. Morris Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study BMJ 315 1997 1199 1201
25. A.R. Folsom, F.J. Nieto, and P. Sorlie Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk in Communities (ARIC) Study Investigators Circulation 98 1998 845 850
26. P.M. Ridker, C.H. Hennekens, and M.J. Stampfer Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke Circulation 98 1998 2796 2799
27. P.M. Ridker, C.H. Hennekens, and J.E. Buring Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women Ann Intern Med 131 1999 573 577
28. P.M. Ridker, R.B. Kundsin, and M.J. Stampfer Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction Circulation 99 1999 1161 1164
29. G.D. Lowe, J.W. Yarnell, and A. Rumley C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 21 2001 603 610
30. J. Cermak, N.S. Key, and R.R. Bach C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 1993 513 520
31. D.A. Sukovich, K. Kauser, and F.D. Shirley Expression of interlukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17 beta-estradiol Arterioscler Thromb Vasc Biol 18 1998 1498 1505
32. T. Khreiss, L. József, and L.A. Potempa Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells Circulation 109 2004 2016 2022
33. S.M. Grundy, T. Bazzarre, and J. Cleeman Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I Circulation 101 2000 E3 E11
34. Expert Panel on Detection EaToHBCiA Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
35. W. Koenig, M. Sund, and M. Froelich C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 Circulation 99 1999 237 242
36. M.A. Mendall, D.P. Strachan, and B.K. Butland C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men Eur Heart J 21 2000 1584 1590
37. J.D. Curb, R.D. Abbott, and B.L. Rodriguez C-reactive protein and the future risk of thromboembolic stroke in healthy men Circulation 107 2003 2016 2020
38. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
39. P.M. Ridker, J.E. Buring, and J. Shih Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women Circulation 98 1998 731 733
40. R.P. Tracy, R.N. Lemaitre, and B.M. Psaty Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project Arterioscler Thromb Vasc Biol 17 1997 1121 1127
41. J.J. Cao, C. Thach, and T.A. Manolio C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study Circulation 108 2003 166 170
42. P.M. Ridker, N. Rifai, and M.A. Pfeffer Inflammation, pravatism, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839 844
43. G. Liuzzo, L.M. Biasucci, and J.R. Gallimore The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med 331 1994 417 424
44. B. Lindahl, H. Toss, and A. Siegbahn Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
45. C. Mueller, H.J. Buettner, and J.M. Hodgson Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients Circulation 105 2002 1412 1415
46. M.N. Zairis, S.J. Manousakis, and A.S. Stefanidis C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction Am Heart J 144 2002 782 789
47. F. Haverkate, S.G. Thompson, and S.D. Pyke Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462 466
48. D.A. Morrow, N. Rifai, and E.M. Antman C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction J Am Coll Cardiol 31 1998 1460 1465
49. US Department of Health, Education, and Welfare Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service 1964 PHS Publication No 1103 Washington, DC
50. E. Durante Mangoni, L.E. Adonolfi, and M.F. Tripodi Risk factors for "major" embolic events in hospitalized patients with infective endocarditis Am Heart J 146 2003 311 316
51. P.M. Ridker, J.E. Buring, and N.R. Cook C-reactive protein, the metabolic syndrome, and risk of incidence cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women Circulation 107 2003 391 397
52. N. Rifai, and P.M. Ridker Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening Clin Chem 47 2001 28 30
53. M.N. Zairis As presented at American Heart Association meeting. Chicago, Illinois 2002
54. T. Sano, A. Tanaka, and M. Namba C-reactive protein and lesion morphology in patients with acute myocardial infarction Circulation 108 2003 282 285
55. H. Toss, B. Lindahl, and A. Siegbahn Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease Circulation 96 1997 4204 4210
56. F. Mach, C. Lovis, and J.M. Gaspoz C-reactive protein as a marker for acute coronary syndromes Eur Heart J 18 1997 1897 1902
57. E.R. Ferreiros, C.P. Boissonnet, and R. Pizarro Independent prognostic value of elevated C-reactive protein in unstable angina Circulation 100 1999 1958 1963
58. D.H. Walter, S. Fichtlscherer, and M. Sellwig Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation J Am Coll Cardiol 37 2001 839 846
59. A. Buffon, G. Liuzzo, and L.M. Biasucci Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty J Am Coll Cardiol 34 1999 1512 1521
60. A. Gaspardone, F. Crea, and F. Versaci Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina Am J Cardiol 82 1998 515 518
61. F. Versaci, A. Gaspardone, and F. Tomai Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation Am J Cardiol 85 2000 92 95
62. D. Milazzo, L.M. Biasucci, and N. Luciani Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events Am J Cardiol 84 1999 459 461 [abstract: A9]
63. TACTICS-TIMI 18 investigators, C.P. Cannon, and W.S. Weintraub High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs conservative strategy in patients with unstable angina. Primary results of the TACTICS-TIMI 18 C-reactive protein substudy J Am Coll Cardiol 37 2001 315A
64. G.S. Heyde, R.J. deWinter, and J. Fischer Prognostic value of C-reactive protein in patients undergoing elective PCI J Am Coll Cardiol 37 2001 27A
65. D.P. Chew, D.L. Bhatt, and M.A. Robbins Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention Circulation 104 2001 992 997
66. Y.F. Zhou, G. Csako, and J.T. Grayston Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels of seropositivity to Chlamydia pneumoniae Am J Cardiol 84 1999 595 598
67. B. Sceller, B. Hennen, and T. Markwirth C reactive protein has no prognostic impact on thrombotic events and target lesion re-intervention rate after coronary stenting J Am Coll Cardiol 37 2001 39A
68. B.D. Horne, J.B. Muhlestein, and G.G. Strobel Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention Am Heart J 144 2002 491 500
69. R.J. de Winter, K.T. Koch, and J.P. van Straalen C-reactive protein and coronary events following percutaneous coronary angioplasty Am J Med 115 2003 85 90
70. T.A. Pearson, G.A. Mensah, and R.W. Alexander Centers for Disease Control and Prevention, American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
71. US Preventive Services Task Force Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions 1989 Williams and Wilkins Bethesda, Md
72. A. Barratt, L. Irwig, and P. Glasziou Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group JAMA 281 1999 2029 2034
73. S.M. Grundy, J.I. Cleeman, and C.N. Merz Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
74. L.K. Heilbronn, M. Noakes, and P.M. Clifton Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women Arterioscler Thromb Vasc Biol 21 2001 968 970
75. R.M. Fleming The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascular disease risk factors Prev Cardiol 5 2002 110 118
76. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
77. I. Ikonomidis, F. Andreotti, and E. Economou Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin Circulation 100 1999 793 798
78. D. Feng, R.P. Tracy, and I. Lipinska Effect of short-term aspirin use on C-reactive protein J Thromb Thrombolysis 9 2000 37 41
79. 2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay J Am Coll Cardiol 37 2001 2036 2041
80. Y.C. Doo, D.M. Kim, and D.J. Oh Effect of β-blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris Am J Cardiol 88 2001 422 444
81. N.P. Jenkins, B.G. Keevil, and I.V. Hutchinson β-Blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease Am J Med 112 2002 269 274
82. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
83. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators N Engl J Med 335 1996 1001 1009
84. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
85. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
86. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
87. P.M. Ridker, N. Rifai, and M.A. Pfeffer Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
88. I. Jialal, D. Stein, and D. Balis Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
89. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia Circulation 103 2001 1191 1193
90. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
91. O. Grip, S. Janciauskiene, and S. Lindgren Pravastatin down-regulates inflammatory mediators in human monocytes in vitro Eur J Pharmacol 410 2000 83 92
92. P.S. Frenette Locking a leukocyte integrin with statins N Engl J Med 345 2001 1419 1421
93. B. Kwak, F. Mulhaupt, and S. Myit Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
94. S. John, C. Delles, and J. Jacobi Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks J Am Coll Cardiol 37 2001 1351 1358
95. S. Kinlay, P. Libby, and P. Ganz Endothelial function and coronary artery disease Curr Opin Lipidol 12 2001 383 389
96. M. Crisby, G. Nordin-Fredriksson, and P.K. Shah Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
97. A.J. Taylor, S.M. Kent, and P.J. Flaherty ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2002 2055 2060
98. S. Kinlay, T. Timms, and M. Clark Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia Am J Cardiol 89 2002 1205 1207
99. T.P. Erlinger, E.R. Miller III, and J. Charleston Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-Sodium trial Circulation 108 2003 150 154
100. P.M. Ridker, N. Rifai, and M. Clearfield Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
101. P.M. Ridker, N. Rifai, and J.S. Miles Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS Circulation 102 2000 II 833
102. P.M. Ridker Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial Eur Heart J 22 2001 2135 2137
103. P.M. Ridker High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 2001 1813 1818
104. P.M. Ridker Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT-TIMI 22) Presented at American Heart Association Scientific Sessions New Orleans, LA 2004